Compare HLN & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLN | RLAY |
|---|---|---|
| Founded | 2022 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.7B | 1.3B |
| IPO Year | N/A | 2020 |
| Metric | HLN | RLAY |
|---|---|---|
| Price | $10.02 | $9.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $16.86 |
| AVG Volume (30 Days) | ★ 8.1M | 2.4M |
| Earning Date | 02-26-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.85% | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | $7.04 | N/A |
| Revenue Next Year | $4.58 | $324.03 |
| P/E Ratio | $49.05 | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $8.71 | $1.78 |
| 52 Week High | $11.42 | $11.49 |
| Indicator | HLN | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 44.95 |
| Support Level | $9.98 | $9.06 |
| Resistance Level | $10.31 | $9.54 |
| Average True Range (ATR) | 0.14 | 0.63 |
| MACD | -0.03 | -0.14 |
| Stochastic Oscillator | 37.37 | 0.90 |
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).